

Subscription price fixed for warrants of series TO1, subscription period begins on October 6, 2022

The subscription price in S2Medical AB (publ) ("S2Medical" or the "Company") option series TO1 has been determined in accordance with the applicable option terms at SEK 0.82. The useful life starts on 6 October 2022 and runs until 20 October 2022. The holder of warrants has the right to subscribe for one (1) new B-share in S2Medical for each warrant at a subscription price of SEK 0.82 per B-share. The subscription price for subscription of Class B shares with the support of warrants of series TO1 corresponds to 70 percent of the volume-weighted average price of the Company's B-share on Nasdaq First North Growth Market during the period 22 August to 30 September 2022. If all warrants of series TO1 are exercised, the Company will receive approximately SEK 12.3 million before issue costs.

Terms and conditions for warrants of series TO1 in summary:

Nyttjandeperiod: 6 oktober – 20 oktober 2022.

Conditions: One (1) warrant entitles the holder to subscribe for one (1) new Class B share.

Tecknings price: SEK 0.82 per B share, courtage utgår ej.

Emissionsvolym: 15,052,083 outstanding warrants of series TO1. A maximum of approximately SEK 12.3 million before issue costs. Upon full use of TO1, the number of B-shares in S2Medical will increase by 15,052,083 B-shares, from 22,463,541 B-shares to 37,515,624 B-shares (the total number of shares will increase to 40,640,624) and the share capital will increase by 881,682,475 from SEK 1,498,860,201 to SEK 2,380,542.676 . Full terms and conditions for TO1 are available through S2Medical's website.

If you have your warrants nominee-registered

In the event that the option holder has his options in a custody account, in an investment savings account or endowment insurance (nominee-registered ownership), subscription and payment shall be made to the respective nominee who instructs on further instructions regarding the method of exercising his warrants.

For more information and for further instructions on how to exercise your warrants, please contact your nominee in good time. Please note that the bank /nominee needs your notification of the exercise of the warrants well in advance of the end of the subscription period.

If you have your warrants directly registered (securities account)

No issue report will be sent out. Subscription of new Class B shares, through the exercise of warrants, shall be made by submitting a fully completed application form to Partner Fondkommission. In connection with the application form being submitted to Partner Fondkommission, payment must be made according to payment instructions on the application form. Completed application form and payment must be received by Partner Fondkommission no later than 15:00 CEST on October 20, 2022. Subscribed and paid B-shares will be registered in your securities account as "interim shares" or "IA" until registration of the issue is completed with the Swedish Companies Registration Office, whereupon interim shares are automatically converted into ordinary shares in S2Medical.

The information was submitted for publication, through the agency of the contact person, on 03-10-2022 19:30 CET.

Kontaktuppgifter

Petter Sivlér – CEO, S2Medical AB (publ)

Telefon: +46 (0)8-70 000 50

E-post: petter.sivler@s2m.se

Certified Adviser

Vator Securities AB

Telefon +46 (0)8-580 065 99

Hemsida: www.vatorsec.se

Epost: ca@vatorsec.se

About S2Medical

S2Medical AB (publ) is a medical technology company that develops and sells innovative wound healing products for the entire wound healing process with a focus on burns and chronic wounds. The company has developed eiratex®, a new cellulose-based material for healing severe burns and chronic wounds. The material heals wounds effectively and thus reduces both suffering for patients and costs for healthcare.

Stock ticker: S2M

The share's ISIN code: SE0011725084